Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow

Clinical Cardiology

Volumn 30, Issue 9, 2007, Pages 475-479

  Caliskan, Mustafa ^a   Erdogan, Dogan ^b   Gullu, Hakan ^a   Topcu, Semra ^a   Ciftci, Ozgur ^a   Yildirir, Aylin ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Atorvastatin; Coronary flow reserve; Echocardiography; Slow coronary flow

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; DIPYRIDAMOLE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MALE; OPEN STUDY; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; TRIGLYCERIDES;

EID: 34548730770     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20140     Document Type: Article

References (19)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
2. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, et al.: ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 2003;361:1149-1158
3. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al.: CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998;339:1349-1357
5. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-1719
6. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E: Angina pectoris and slow flow velocity of dye in coronary arteries. A new angiographic finding. Am Heart J 1972;84:66-71
7. Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A: et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996;37:375-381
8. Caiati C, Zedda N, Montaldo C, Montisci R, Iliceto S: Contrast-enhanced transthoracic second harmonic echo Doppler with adenosine: a noninvasive, rapid and effective method for coronary flow reserve assessment. J Am Coll Cardiol 1999;34:122-130
9. Britten MB, Zeiher AM, Schachinger V Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome. Coron Artery Dis 2004;15:259-264
10. Caiati C, Montaldo C, Zedda N Bina A, Iliceto S New noninvasive method for coronary flow reserve assessment: contrast-enhanced transthoracic second harmonic echo Doppler. Circulation 1999;99:771-778
11. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-888
12. Erdogan D, Gullu H, Caliskan M, Yildirim I, Tok D, et al.: Coronary flow reserve is preserved in white-coat hypertension. Heart 2006;92:1109-1112
13. De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, et al.: Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography. Circulation 2001;104:2401-2406
14. Mosseri M, Yarom R, Gotsman MS, Hasin Y Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986;5:964-972
15. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, et al.: Benefits of statin treatment in cardiac syndrome-X. Eur Heart J 2003;24:1999-2005
16. Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, et al.: Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999;99:2871-2875
17. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999;33:234-241
18. Ling MC, Ruddy TD, deKemp RA, Ukkonen H, Duchesne L, et al. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. Am Heart J 2005;149:1137
19. Hinoi T, Matsuo S, Tadehara F, Tsujiyama S, Yamakido M Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 2005;96:89-91